方盛制药：方盛制药关于控股子公司中药创新药研发项目获得药物临床试验批准通知书的公告

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, Fangsheng R&D, has received approval from the National Medical Products Administration for clinical trials of its innovative traditional Chinese medicine, Ziying Granules [1] - Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine and is developed for the treatment of chronic pelvic pain, a sequela of pelvic inflammatory disease [1] - The product is based on years of clinical experience in treating pelvic inflammatory disease and has not yet been launched in domestic or international markets [1]